间充质干细胞治疗疑难肝病的机遇与挑战  

Mesenchymal stem cells for the treatment of end-stage liver diseases: opportunities and challenges

作　　者：徐若男[1] 林沪[1] 吕飒[1] 王福生[1] 

机构地区：[1]解放军第302医院生物治疗研究中心,北京100039

出　　处：《中华细胞与干细胞杂志（电子版）》2014年第4期42-45,共4页Chinese Journal of Cell and Stem Cell（Electronic Edition）

摘　　要：间充质干细胞(MSC)是一群来源于中胚层的多能干细胞,具有多项分化发育潜能。MSC的多潜能性、可扩增性、取材广泛性(骨髓、脐带、脐带血、羊膜、脂肪等组织)等诸多特点为其临床应用奠定了重要基础。在国外,MSC已经获得了临床新药批号,用于移植物抗宿主病(GVHD)的治疗。此外,在心血管疾病、骨及软骨损伤、血液系统疾病、肝脏疾病和自身免疫性疾病等方面,也展示了良好的安全性和初步疗效。尤其是在疑难肝病例如:急性肝衰竭、慢加急性肝衰和失代偿性肝硬化等的临床治疗中也取得了一定效果。疑难肝病的死亡率高,治疗手段有限,需要研发新型、有效的治疗手段来降低死亡率。本文将分析本领域的相关进展,同时分析有关需要解决的问题。Mesenchymal stem cells （MSC） are adults stem cells mat originate from bone marrow, umbilical cord, cord blood, amniotic membrane, adipose tissue, etc. These cells show self-renewal and multidirectional differentiation potential, which are important for their application. Now, MSC have been authorized to treat graft-versus-host disease as a novel drug. In addition, MSC have been documented for their safety and preliminary efficacy in cardiovascular disease, severe osteogenesis imperfect, hematological disease, autoimmune disease, and liver disease including acute liver failure, acute-on-chronic liver failure and decompensated liver cirrhosis. To date, treatment options of end-stage liver diseases are limited and exclusively supportive. In this respect, more therapeutic strategies are needed in order to reduce the mortality. This review focuses on potentially relevant development in this field and analyzes the associated problems.

关 键 词：间充质干细胞 安全性 死亡率 肝病 

分 类 号：R575[医药卫生—消化系统]